A Phase II trial of Genentech‘s Avastin showed that the MAb, administered alone or in combination with irinotecan chemotherapy, demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer. As assessed by independent radiological review, 36% of GBM patients treated with Avastin alone, and 51% of patients treated with Avastin in combination with chem...